Probing the role of linker substituents in bisdioxopiperazine analogs for activity against wild-type and mutant human topoisomerase IIα

Molecular Pharmacology

Volumn 63, Issue 5, 2003, Pages 1159-1168

  Renodon Cornière, Axelle ^a   Sørensen, Tina K ^a,c   Jensen, Peter B ^a,c   Nitiss, John L ^b   Søkilde, Birgitte ^c   Sehested, Maxwell ^a,c   Jensen, Lars H ^a,c  

^a International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c BioAlliance Pharma   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 BIS(3,5 DIOXOPIPERAZIN 1 YL)ETHANE; DNA TOPOISOMERASE (ATP HYDROLYSING); MITINDOMIDE; PIPERAZINE DERIVATIVE; PIPERAZINEDIONE;

ARTICLE; CHROMATIN CONDENSATION; COMPLEX FORMATION; DNA DAMAGE; DNA RECOMBINATION; DNA REPLICATION; DRUG ACTIVITY; GENE MUTATION; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; TARGET CELL;

ADENOSINE TRIPHOSPHATE; ANTIGENS, NEOPLASM; CATALYSIS; DNA; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; ENZYME INHIBITORS; GENETIC COMPLEMENTATION TEST; HUMANS; INDOLES; MUTAGENESIS, SITE-DIRECTED; PIPERAZINES; RAZOXANE; YEASTS;

EID: 0038068957     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.63.5.1159     Document Type: Article

References (31)

1. Andoh T and Ishida R (1998) Catalytic inhibitors of DNA topoisomerase II. Biochim Biophys Acta 1400:155-171.
2. Chang S, Hu T, and Hsieh TS (1998) Analysis of a core domain in Drosophila DNA topoisomerase II. Targeting of an antitumor agent ICRF-159. J Biol Chem 273:19822-19828.
3. Chen AY and Liu LF (1994) DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 34:191-218.
4. Hasinoff BB, Creighton AM, Kozlowska H, Thampatty P, Allan WP, and Yalowich JC (1997) Mitindomide is a catalytic inhibitor of DNA topoisomerase II that acts at the bisdioxopiperazine binding site. Mol Pharmacol 52:839-845.
5. Holm B, Jensen PB, and Sehested M (1996) ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors. Cancer Chemother Pharmacol 38:203-209.
6. Holm B, Sehested M, and Jensen PB (1998) Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide. Clin Cancer Res 4:1367-1373.
7. Hsiung Y, Jannatipour M, Rose A, McMahon J, Duncan D, and Nitiss JL (1996) Functional expression of human topoisomerase II alpha in yeast: mutations at amino acids 450 or 803 of topoisomerase II alpha result in enzymes that can confer resistance to anti-topoisomerase II agents. Cancer Res 56:91-99.
8. Hu T, Sage H, and Hsieh TS (2002) ATPase domain of eukaryotic DNA topoisomerase II. Inhibition of ATPase activity by the anti-cancer drug bisdioxopiperazine and ATP/ADP-induced dimerization. J Biol Chem 277:5944-5951.
9. Huang KC, Gao H, Yamasaki EF, Grabowski DR, Liu S, Shen LL, Chan KK, Ganapathi R, and Snapka RM (2001) Topoisomerase II poisoning by ICRF-193. J Biol Chem 276:44488-44494.
10. Jensen LH, Nitiss KC, Rose A, Dong J, Zhou J, Hu T, Osheroff N, Jensen PB, Sehested M, and Nitiss JL (2000a) A novel mechanism of cell killing by antitopoisomerase II bisdioxopiperazines. J Biol Chem 275:2137-2146.
11. Jensen LH, Renodon-Cornière A, Wessel I, Langer SW, Sokilde B, Carstensen EV, Sehested M, and Jensen PB (2002) Maleimide is a potent inhibitor of topoisomerase II in vitro and in vivo: a new mode of catalytic inhibition. Mol Pharmacol 61:1235-1243.
12. Jensen LH, Wessel I, Moller M, Nitiss JL, Sehested M, and Jensen PB (2000b) N-Terminal and core-domain random mutations in human topoisomerase II alpha conferring bisdioxopiperazine resistance. FEBS Lett 480:201-207.
13. Jensen PB and Sehested M (1997) DNA topoisomerase II rescue by catalytic inhibitors: a new strategy to improve the antitumor selectivity of etoposide. Biochem Pharmacol 54:755-759.
14. Langer SW, Sehested M, and Jensen PB (2000) Treatment of anthracycline extravasation with dexrazoxane. Clin Cancer Res 6:3680-3686.
15. Liu LF (1989) DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58:351-375.
16. Morris SK, Baird CL, and Lindsley JE (2000) Steady-state and rapid kinetic analysis of topoisomerase II trapped as the closed-clamp intermediate by ICRF-193. J Biol Chem 275:2613-2618.
17. Nitiss JL (1994) Roles of DNA topoisomerases in chromosomal replication and segregation. Adv Pharmacol 29A:103-134.
18. 2-terminal fragments of yeast DNA topoisomerase II. J Biol Chem 274:21688-21694.
19. Patel S, Jazrawi E, Creighton AM, Austin CA, and Fisher LM (2000) Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIa. Mol Pharmacol 58:560-568.
20. Renodon-Cornière A, Jensen LH, Nitiss JL, Jensen PB, and Sehested M (2002) Interaction of human topoisomerase II a with DNA. Quantitation by SPR assay. Biochemistry 41:13395-13402.
21. Roca J, Ishida R, Berger JM, Andoh T, and Wang JC (1994) Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci USA 91:1781-1785.
22. Roca J and Wang JC (1992) The capture ofa DNA double helix by an ATP-dependent protein clamp: a key step in DNA transport by type II DNA topoisomerases. Cell 71:833-840.
23. Roca J and Wang JC (1994) DNA transport by a type II DNA topoisomerase: evidence in favor of a two-gate mechanism. Cell 77:609-616.
24. Sahai BM and Kaplan JG (1986) A quantitative decatenation assay for type II topoisomerases. Anal Biochem 156:364-379.
25. Sehested M, Wessel I, Jensen LH, Holm B, Oliveri RS, Kenwrick S, Creighton AM, Nitiss JL, and Jensen PB (1998) Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers highlevel resistance to bisdioxopiperazines. Cancer Res 58:1460-1468.
26. van Hille B and Hill BT (1998) Yeast cells expressing differential levels of human or yeast DNA topoisomerase II: a potent tool for identification and characterization of topoisomerase II-targeting antitumour agents. Cancer Chemother Pharmacol 42:345-356.
27. Wang JC (1996) DNA topoisomerases. Annu Rev Biochem 65:635-692.
28. Wasserman RA, Austin CA, Fisher LM, and Wang JC (1993) Use of yeast in the study of anticancer drugs targeting DNA topoisomerases: expression of a functional recombinant human DNA topoisomerase II alpha in yeast. Cancer Res 53:3591-3596.
29. Wessel I, Jensen LH, Jensen PB, Falck J, Rose A, Roerth M, Nitiss JL, and Sehested M (1999) Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the walker A consensus ATP binding domain of the alpha isoform. Cancer Res 59:3442-3450.
30. Wessel I, Jensen LH, Renodon-Cornière A, Sorensen TK, Nitiss JL, Jensen PB, and Sehested M (2002) Human small cell lung cancer NYH cells resistant to the bisdioxopiperazine ICRF-187 exhibit a functional dominant Tyr165Ser mutation in the walker A ATP binding site of topoisomerase IIalpha. FEBS Lett 520:161-166.
31. Worland ST and Wang JC (1989) Inducible overexpression, purification and active site mapping of DNA topoisomerase II from the yeast Saccharomyces cerevisiae. J Biol Chem 264:4412-4416.